"We anticipate that our medical devices business will comprise
about 25% of our revenues over the next three years, enhancing organisational value."
Overview
Plastics are essential to modern life, playing a critical role in
lifesaving advancements in medicine, insulation, heating applications and transportation.
Their ability to replace natural materials without compromising a high strength-to-weight
ratio has made several products cheaper, lighter, safer and stronger. By doing so,
plastics have emerged as critical to humankind.
The engineering plastic molding industry is vast and expanding
globally, with specialists in the packaging, consumer goods, automotive, white goods,
electronics, and healthcare sectors. I am pleased to communicate that Shaily is one of
those specialists; the Company has strengthened its position in the global consumer goods
and healthcare segments.
Over the years, Shaily has deepened its effectiveness within the global
plastic molding space. The Company proactively restructured its business around specific
verticals—Healthcare, Consumer, and Specialty—based on shared processes and
material similarities. The Company invested in adequate processing capacity, demonstrating
its readiness to engage in long-term partnerships with customers. Shaily has chosen to
operate in technology niches characterised by relatively low competition. The Company has
strengthened its Balance Sheet, empowering it to invest proactively in capacity building.
Shaily has progressively enhanced its intellectual property within its
areas of focus, emerging as a go-to value-enhancing partner. By the end of the last
financial year, the Company had established seven patent platforms through its UK
subsidiary; it plans to extend this capacity and knowledge to other verticals. This
commitment is likely to empower the Company to transition from one-off transactions to
multi-year engagements with the same customers, enhancing revenue visibility.
Shaily?s specialist positioning is its principal asset. The
Company is expected to attract a broader range of global customers. Its IP-led approach is
anticipated to deepen business credentials, especially in the pharmaceuticals sector,
where drug registrations require a stable combination of drug and safe device
manufacturing. This is expected to enhance Shaily?s reputation as a research-led
solutions provider.
- room comprising advanced technologies; this has deepened our
capability to produce high-precision tools and molds. These advancements will accelerate
product development, improve manufacturing precision and enhance product customisation.
An important part of our business investment includes a commitment to
align with evolving environmental, social, and governance (ESG) standards.
Shaily has progressively enhanced its intellectual property within its
areas of focus, emerging as a go-to value-enhancing partner. By the end of the last
financial year, the company had established seven patent platforms through its UK
subsidiary; it plans to extend this capacity and knowledge to other verticals. This
commitment is likely to empower the company to transition from one-off transactions to
multi-year engagements with the same customers, enhancing revenue visibility.
Shaily has invested in segments with enduring potential that are likely
to generate long-term value. The Company is focused on creating intellectual property for
specialised medical devices that include medical devices for weight loss combination
drugs, a niche area. This visibility has facilitated discussions with large global generic
companies regarding solution development. The medical device business has continued to
demonstrate a resilience to economic changes, marked by a growing global need for
therapies and blockbuster drugs.
Shaily is attractively positioned to capitalise on high-precision
engineering capabilities. Looking ahead, the Company expects that pharmaceuticals will
comprise about 25% of its revenues over three years Shaily is proactively prepared to
drive business sustainability. The Company has made timely and significant investments in
a state-of-the-art tool
The Company has demonstrated its commitment to environment
responsibility by implementing energy-efficient processes and increasing the use of
recycled materials. Its social commitment is manifested in fair labour practices and
community contributions. Governance has been showcased through the highest standards of
ethical conduct, recruitment of experienced professionals, deepening of research, enhanced
operational efficiency, and maintaining the highest quality standards.
I am confident that these strategic priorities have reinforced
Shaily?s preparedness to seize opportunities in a transforming world and strengthen
its business sustainability.
Mahendra (Mike) Sanghvi
Executive Chairman